ArticleDEN open2026
Prevention of Cholangitis by Spontaneously Dislodging Biliary Stent After an Endoscopic Procedure in Patients With Asymptomatic Bile Duct Stones.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effectiveness of spontaneously dislodging biliary stent (SDBS) placement in preventing acute cholangitis after endoscopic retrograde cholangiopancreatography (ERCP) in patients with asymptomatic bile duct stones. Methods: This retrospective, single-center study included 63 patients (mean age, 73 ± 11 years; 43 men) who underwent ERCP for asymptomatic bile duct stones at our institute between April 2022 and May 2024; they were categorized into the SDBS (33 patients) and non-stent (30 patients) groups. Stone removal was performed in all cases, and complete stone clearance was achieved. Post-procedure cholangitis was diagnosed based on the Tokyo Guidelines 2018. The primary endpoint was post-procedural acute cholangitis on day one. Secondary endpoints included cholangitis-related factors, type of device used, procedure time, and adverse events other than cholangitis. Multivariate analysis was performed to identify factors associated with post-procedure cholangitis. Results: No significant differences were observed in prior cholecystectomy, bile duct diameter, or the number of stones between the two groups. The overall incidence of post-procedure cholangitis was 17.4%. The incidence was significantly lower in the SDBS group than in the non-stent group (6% vs. 30%; Conclusion: SDBS placement may be effective in preventing cholangitis after ERCP in asymptomatic patients with bile duct stones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.